Sep 09, 2021 / 02:40PM GMT
Andrew Simon Baum - Citigroup Inc., Research Division - Global Head of Healthcare Research and MD
So welcome back, delighted to introduce our next session with the management of Royalty Pharma. Introducing a former colleague, Chris Hite, now Vice Chairman of Royalty; and Terrance Coyne, Chief Financial Officer of Royalty Pharma, which we participated in the IPO earlier last year actually.
So on that note, before we get into Q&A and because it is a relatively unique business model, which not all the investor base is familiar with, we're going to spend a little bit of time summarizing the structure, the strategy and the outlook for the company before we go to the Q&A. So handing it over to Terrance and Chris to take you on [aboard] that you like. Thank you for joining us again.
Christopher Hite - Royalty Pharma plc - Vice Chairman & Executive VP
Thank you, Andrew, and good afternoon, everyone. It is a pleasure to be here to discuss Royalty Pharma and share why we are so excited about the future of our business. On this slide, you can see our
Royalty Pharma PLC at Citi BioPharma Conference (Virtual) Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers